EP4272757A3 - Modified nk-92 cells for treating cancer - Google Patents

Modified nk-92 cells for treating cancer Download PDF

Info

Publication number
EP4272757A3
EP4272757A3 EP23176181.8A EP23176181A EP4272757A3 EP 4272757 A3 EP4272757 A3 EP 4272757A3 EP 23176181 A EP23176181 A EP 23176181A EP 4272757 A3 EP4272757 A3 EP 4272757A3
Authority
EP
European Patent Office
Prior art keywords
cells
modified
treating cancer
car
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23176181.8A
Other languages
German (de)
French (fr)
Other versions
EP4272757A2 (en
Inventor
Tien Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of EP4272757A2 publication Critical patent/EP4272757A2/en
Publication of EP4272757A3 publication Critical patent/EP4272757A3/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.
EP23176181.8A 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer Pending EP4272757A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562173701P 2015-06-10 2015-06-10
US201662337044P 2016-05-16 2016-05-16
PCT/US2016/036991 WO2016201304A1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer
EP16808427.5A EP3307876B1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP16808427.5A Division EP3307876B1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer
EP16808427.5A Division-Into EP3307876B1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Publications (2)

Publication Number Publication Date
EP4272757A2 EP4272757A2 (en) 2023-11-08
EP4272757A3 true EP4272757A3 (en) 2023-12-27

Family

ID=57504144

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23176181.8A Pending EP4272757A3 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer
EP16808427.5A Active EP3307876B1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16808427.5A Active EP3307876B1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Country Status (10)

Country Link
US (3) US10738279B2 (en)
EP (2) EP4272757A3 (en)
JP (3) JP2018517415A (en)
KR (3) KR102526538B1 (en)
CN (2) CN107709552B (en)
AU (1) AU2016275030B2 (en)
CA (1) CA2987290C (en)
ES (1) ES2958720T3 (en)
IL (2) IL309167A (en)
WO (1) WO2016201304A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2839089T3 (en) 2014-05-15 2021-07-05 Nat Univ Singapore Modified natural killer lymphocytes and their uses
CN107709552B (en) 2015-06-10 2022-05-13 南克维斯特公司 Modified NK-92cells for the treatment of cancer
CN108174604B (en) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） Bispecific CAR T cells for solid tumor targeting
KR102469703B1 (en) 2016-06-08 2022-11-23 프레시전 인코포레이티드 CD33 specific chimeric antigen receptor
WO2018129346A1 (en) * 2017-01-06 2018-07-12 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
US11692194B2 (en) * 2017-01-10 2023-07-04 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
AU2018214558B2 (en) * 2017-02-01 2020-08-27 Immunitybio, Inc. Calreticulin-mediated cancer treatment
WO2018152516A1 (en) * 2017-02-20 2018-08-23 Adimab, Llc Proteins binding cd33, nkg2d and cd16
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. Targeted immunotolerance
CN117363636A (en) 2017-03-27 2024-01-09 新加坡国立大学 Polynucleotide encoding chimeric receptor
KR20190126182A (en) * 2017-03-27 2019-11-08 난트셀, 인크. aNK and IL-12 COMPOSITIONS AND METHODS
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11655306B2 (en) * 2017-04-05 2023-05-23 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
JP2020516654A (en) * 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド Combination cancer immunotherapy
MX2019013517A (en) 2017-05-24 2020-08-17 Pandion Operations Inc Targeted immunotolerance.
TWI676483B (en) * 2017-08-06 2019-11-11 強普生技股份有限公司 Pharmaceutical kit and uses thereof
EP3697438A4 (en) * 2017-10-18 2021-08-18 Intrexon Corporation Polypeptide compositions comprising spacers
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells
US20210187024A1 (en) * 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
WO2019101998A1 (en) 2017-11-24 2019-05-31 Onkimmune Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN110028589B (en) * 2018-02-07 2023-07-21 阿思科力(苏州)生物科技有限公司 Chimeric antigen receptor, NKG2D CAR-NK cell expressing chimeric antigen receptor, and preparation method and application thereof
CN112004829A (en) * 2018-03-12 2020-11-27 南克维斯特公司 Use of CD33 CAR-modified high affinity NK cells (T-HANKs) for reducing the inhibitory activity (or reducing the negative impact on NK cell activity) of myeloid derived suppressor cells
WO2019182422A1 (en) * 2018-03-23 2019-09-26 주식회사 에스엘바이젠 Novel genetically modified natural killer cell line and use thereof
KR20240001720A (en) * 2018-05-22 2024-01-03 난트퀘스트, 인크. Fc-epsilon car
US10960024B2 (en) * 2018-08-01 2021-03-30 Nantkwest, Inc. Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
CA3092709A1 (en) * 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells
AU2019370094B2 (en) * 2018-10-31 2022-02-03 Nantkwest, Inc. Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
CA3092305A1 (en) 2018-11-06 2020-05-14 Nantkwest, Inc. Chimeric antigen receptor-modified nk-92 cells
US20220017594A1 (en) * 2018-11-26 2022-01-20 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
CA3131533A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US11364265B1 (en) 2019-03-15 2022-06-21 Nantcell, Inc. Recombinant erIL-15 NK cells
JP2022533702A (en) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM-targeted immune tolerance
US20220265716A1 (en) * 2019-07-26 2022-08-25 Nantkwest, Inc. Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
AU2019459423B2 (en) * 2019-08-01 2023-06-01 Immunitybio, Inc. Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
WO2021054789A1 (en) * 2019-09-18 2021-03-25 주식회사 에스엘바이젠 Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof
US20210106619A1 (en) * 2019-10-10 2021-04-15 Nantkwest, Inc. NK-92 Bone and Brain targeting
EP4061385A1 (en) * 2019-11-19 2022-09-28 Acibadem Mehmet Ali Aydinlar Üniversitesi A method for redesign and expansion of nk92 cells for use in immunotherapy
CN115190910A (en) * 2019-11-20 2022-10-14 免疫生物公司 Cell-mediated transient delivery of immune enhancing molecules into the tumor microenvironment
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021154218A1 (en) * 2020-01-28 2021-08-05 Nantkwest, Inc. Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
EP4097220A4 (en) * 2020-01-30 2024-03-20 Immunitybio Inc Elimination of bcma-positive malignancies by car expressing nk cells
AU2021305084A1 (en) 2020-07-07 2023-02-02 Cancure, Llc MIC antibodies and binding agents and methods of using the same
US20220401485A1 (en) * 2020-08-11 2022-12-22 Immunitybio, Inc. Chimeric Antigen Receptor-Modified NK-92 Cells
MX2023004811A (en) * 2020-10-26 2023-06-29 Res Institute At Nationwide Children´S Hospital Chimeric antigen receptor (car) nk cells and uses thereof.
TW202237826A (en) 2020-11-30 2022-10-01 瑞士商克里斯珀醫療股份公司 Gene-edited natural killer cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123754A1 (en) * 2007-01-30 2009-11-25 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
WO2014055668A1 (en) * 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
DE69834257T2 (en) 1997-04-30 2007-01-04 Klingemann, Hans NATURAL KILLER CELL LINES AND METHOD FOR THEIR USE
JP2001522603A (en) 1997-11-06 2001-11-20 ロシュ ダイアグノスティックス ゲーエムベーハー Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO2000020460A1 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
SE526227C2 (en) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Method of purifying recombinant human serum albumin
BR0311471A (en) 2002-05-30 2007-04-27 Macrogenics Inc anti-cd16a antibody, and methods for reducing a deleterious immune response in a mammal and treating a deleterious immune response in a mammal
EP1781777A1 (en) * 2004-07-02 2007-05-09 Avaris AB Method for the genetic activation of cells and uses of said cells
DK2801583T3 (en) * 2004-07-10 2018-07-16 Fox Chase Cancer Center Genetically modified human natural killer cell lines
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
ES2602743T3 (en) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
SG10201510092QA (en) * 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6053688B2 (en) 2011-10-07 2016-12-27 国立大学法人三重大学 Chimeric antigen receptor
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CN103483452B (en) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 Dual signal independent chimeric antigen receptors and uses thereof
CA2883502C (en) 2012-09-04 2021-05-04 Cellectis Multi-chain chimeric antigen receptor and uses thereof
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
US9745368B2 (en) * 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
ES2777940T3 (en) * 2013-05-03 2020-08-06 Ohio State Innovation Foundation Immune effector cells genomanipulated with a CS1-specific chemical antigen receptor
CN104561069A (en) * 2013-10-23 2015-04-29 深圳先进技术研究院 Micro-annullus DNA recombinant plasmid containing recombinant chimeric antigen receptor gene expression box, micro-annullus DNA containing expression box and application
JP6603216B2 (en) * 2013-11-01 2019-11-06 ナントクエスト インコーポレイテッド Tumoricidal and antibacterial compositions and methods
BR112016011460A2 (en) * 2013-11-21 2017-09-26 Ucl Business Plc cell
CN107709552B (en) 2015-06-10 2022-05-13 南克维斯特公司 Modified NK-92cells for the treatment of cancer
CA3092709A1 (en) * 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123754A1 (en) * 2007-01-30 2009-11-25 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
WO2014055668A1 (en) * 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOISSEL LAURENT ET AL: "Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.", ONCOIMMUNOLOGY 01 OCT 2013, vol. 2, no. 10, 1 October 2013 (2013-10-01), pages e26527, XP055311963, ISSN: 2162-4011 *
BOISSEL LAURENT ET AL: "Transfection of NK Cells with mRNA or Lentivirus Expressing Chimeric Antigen Receptors Results in Highly Efficient Killing of Lymphoid Malignancies and Compares Favorably with Monoclonal Antibody-Directed ADCC", vol. 114, no. 22, 8 December 2009 (2009-12-08), pages 675 - 676, XP008177689, ISSN: 0006-4971, Retrieved from the Internet <URL:http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1696?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=transfection+of+NK+cells&searchid=1&FIRSTINDEX=0&volume=114&issue=22&resourcetype=HWCIT> *

Also Published As

Publication number Publication date
CA2987290A1 (en) 2016-12-15
JP2021097694A (en) 2021-07-01
EP3307876A4 (en) 2019-04-03
US20240002802A1 (en) 2024-01-04
CN107709552A (en) 2018-02-16
US11788059B2 (en) 2023-10-17
KR20230062879A (en) 2023-05-09
EP3307876B1 (en) 2023-09-13
CN107709552B (en) 2022-05-13
US20180163176A1 (en) 2018-06-14
KR20240013282A (en) 2024-01-30
JP7275178B2 (en) 2023-05-17
AU2016275030A1 (en) 2017-12-14
ES2958720T3 (en) 2024-02-13
CA2987290C (en) 2023-10-03
WO2016201304A1 (en) 2016-12-15
IL255884A (en) 2018-01-31
JP2018517415A (en) 2018-07-05
KR102526538B1 (en) 2023-04-28
EP4272757A2 (en) 2023-11-08
KR20180008862A (en) 2018-01-24
IL309167A (en) 2024-02-01
AU2016275030B2 (en) 2021-12-09
CN113502270A (en) 2021-10-15
KR102627811B1 (en) 2024-01-24
IL255884B1 (en) 2024-01-01
EP3307876A1 (en) 2018-04-18
US20210054337A1 (en) 2021-02-25
JP2023054220A (en) 2023-04-13
US10738279B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
EP4272757A3 (en) Modified nk-92 cells for treating cancer
WO2018190719A3 (en) Anti-sirp alpha antibodies
WO2016025635A3 (en) Combination therapy for treating cancer
MX2018002723A (en) Peptidomimetic macrocycles and uses thereof.
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2015191934A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
SG10201902664RA (en) Combination therapy for treating cancer
WO2014089241A3 (en) Molecular profiling for cancer
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2011056688A3 (en) Molecular profiling for personalized medicine
WO2016043874A3 (en) Combination therapy for treating cancer
WO2014169078A3 (en) 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
EA201201464A1 (en) NEW COMBINED THERAPY FOR THE TREATMENT OF CANCER AND FIBROUS DISEASES
CL2012002217A1 (en) Isolated polypeptide comprising at least one single domain variable monomer of an nb agent that binds to human dr5; method for the prevention and / or treatment of a disorder that can be treated by improving cell apoptosis.
WO2014151456A3 (en) Treatment of inflammatory diseases
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
MX2023000796A (en) Pharmaceutical composition, methods for treating and uses thereof.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
BR112012022552A2 (en) use of fenoterol and fenoterol analogs in the treatment of gliobastomas and astrocytomas
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201790563A8 (en) APPLICATION OF WOODLIZUMAB FOR THE TREATMENT OF EOSINOPHIL ASTHMA WITH A DEGREE OF DIFFERENCE TO HEAVY
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3307876

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: C12N0005078300

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20231117BHEP

Ipc: A61K 39/00 20060101ALI20231117BHEP

Ipc: A61K 35/17 20150101ALI20231117BHEP

Ipc: C07K 16/28 20060101ALI20231117BHEP

Ipc: C07K 14/735 20060101ALI20231117BHEP

Ipc: C07K 14/725 20060101ALI20231117BHEP

Ipc: C07K 14/54 20060101ALI20231117BHEP

Ipc: C12N 5/0783 20100101AFI20231117BHEP